You are here

Article Text

Article menu
Download PDFPDF
CORRESPONDENCE AND BRIEF REPORT
Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma
  1. N. Arora*,
  2. D. Tewari†,
  3. C. Cowan*,
  4. B. Saffari*,
  5. B. J. Monk* and
  6. R. A. Burger*
  1. * Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, California and
  2. † Oregon Health Sciences University, Portland, Oregon
  1. Address correspondence and reprint requests to: Devansu Tewari, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oregon Health Sciences University, L466, 3181 SW Sam Jackson Park Road, Portland, OR 97239-3098, USA. Email: dtewari1{at}gmail.com

Abstract

The targeting of angiogenesis pathways in the treatment of gynecological cancers is an exciting development in cancer therapy. Bevacizumab has been shown to have activity in ovarian cancer through its inhibition of the vascular endothelial growth factor. Fallopian tube carcinoma is a rare malignancy and is often treated in a similar manner as ovarian carcinoma. We present a case of a complete response in a woman with refractory metastatic fallopian tube carcinoma treated with bevacizumab. This report demonstrates the significance of anti-angiogenesis therapy in the treatment of these tumors.

  • angiogenesis
  • bevacizumab
  • fallopian tube cancer

http://dx.doi.org/10.1111/j.1525-1438.2007.01026.x

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.